Hypoparathyroidism future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
m (Bot: Removing from Primary care) |
|||
| (11 intermediate revisions by one other user not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Hypoparathyroidism}} | {{Hypoparathyroidism}} | ||
{{CMG}}; {{AE}} | {{CMG}}; {{AE}} {{Anmol}} | ||
==Overview== | ==Overview== | ||
In 1996, Winer and collegues demonstrated a reduction in [[calcium]] [[excretion]] in patients of hypoparathyroidism when treated with PTH 1-34 ([[teriparatide]]) when compared with treatment with [[calcitriol]] and [[calcium]]. PTH 1–34 ([[teriparatide]]) twice daily administered [[Subcutaneous injection|subcutaneoulsy]] provides a safe and effective alternative to [[calcitriol]] therapy and is capable of maintaining normocalcemia without [[hypercalciuria]] for at least 3 yr in patients with hypoparathyroidism. PTH 1-34 ([[teriparatide]]) has shown to improve the mental and physical health in hypoparathyroid patients. | |||
==Future or Investigational Therapies== | ==Future or Investigational Therapies== | ||
===Parathyroid hormone 1-34 (teriparatide)== | ===Parathyroid hormone 1-34 (teriparatide)=== | ||
*In 1996, Winer and collegues demonstrated a reduction in | *In 1996, Winer and collegues demonstrated a reduction in [[calcium]] [[excretion]] in patients of hypoparathyroidism when treated with [[PTH 1-34]] ([[teriparatide]]) when compared with treatment with [[calcitriol]] and [[Calcium supplement|calcium]].<ref name="pmid8773636">{{cite journal |vauthors=Winer KK, Yanovski JA, Cutler GB |title=Synthetic human parathyroid hormone 1-34 vs calcitriol and calcium in the treatment of hypoparathyroidism |journal=JAMA |volume=276 |issue=8 |pages=631–6 |year=1996 |pmid=8773636 |doi= |url=}}</ref> | ||
*Synthetic human | *Synthetic human was approved as a treatment for severe [[osteoporosis]] in 2002. | ||
*PTH 1-34 has shown to improve the mental and physical health in hypoparathyroid | *[[PTH 1–34]] ([[teriparatide]]) twice-daily shown to provide effective treatment of hypoparathyroidism and reduces the fluctuation in [[serum]] [[calcium]] levels at a lower total daily [[parathyroid hormone]] dose when compared to once daily regimen.<ref name="pmid9768650">{{cite journal |vauthors=Winer KK, Yanovski JA, Sarani B, Cutler GB |title=A randomized, cross-over trial of once-daily versus twice-daily parathyroid hormone 1-34 in treatment of hypoparathyroidism |journal=J. Clin. Endocrinol. Metab. |volume=83 |issue=10 |pages=3480–6 |year=1998 |pmid=9768650 |doi=10.1210/jcem.83.10.5185 |url=}}</ref> | ||
*[[PTH 1–34]] ([[teriparatide]]) twice daily administered [[Subcutaneous injection|subcutaneoulsy]] provides a safe and effective alternative to [[calcitriol]] therapy and is capable of maintaining normocalcemia without [[hypercalciuria]] for at least 3 yr in patients with hypoparathyroidism.<ref name="pmid12970289">{{cite journal |vauthors=Winer KK, Ko CW, Reynolds JC, Dowdy K, Keil M, Peterson D, Gerber LH, McGarvey C, Cutler GB |title=Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone-(1-34) versus calcitriol and calcium |journal=J. Clin. Endocrinol. Metab. |volume=88 |issue=9 |pages=4214–20 |year=2003 |pmid=12970289 |doi=10.1210/jc.2002-021736 |url=}}</ref> | |||
*[[PTH 1–34]] ([[teriparatide]]) is also safe and effective for treatment children with hypoparathyroidism when compared with [[Hypoparathyroidism medical therapy#Medical Therapy|conventional therapy]].<ref name="pmid20392870">{{cite journal |vauthors=Winer KK, Sinaii N, Reynolds J, Peterson D, Dowdy K, Cutler GB |title=Long-term treatment of 12 children with chronic hypoparathyroidism: a randomized trial comparing synthetic human parathyroid hormone 1-34 versus calcitriol and calcium |journal=J. Clin. Endocrinol. Metab. |volume=95 |issue=6 |pages=2680–8 |year=2010 |pmid=20392870 |pmc=2902068 |doi=10.1210/jc.2009-2464 |url=}}</ref> | |||
*[[PTH 1–34]] ([[teriparatide]]) has shown to improve the mental and physical health in hypoparathyroid patients.<ref name="pmid26196949">{{cite journal |vauthors=Santonati A, Palermo A, Maddaloni E, Bosco D, Spada A, Grimaldi F, Raggiunti B, Volpe R, Manfrini S, Vescini F |title=PTH(1-34) for Surgical Hypoparathyroidism: A Prospective, Open-Label Investigation of Efficacy and Quality of Life |journal=J. Clin. Endocrinol. Metab. |volume=100 |issue=9 |pages=3590–7 |year=2015 |pmid=26196949 |doi=10.1210/jc.2015-1855 |url=}}</ref> | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
{{WS}} | |||
{{WH}} | |||
[[Category:Needs content]] | [[Category:Needs content]] | ||
[[Category:Endocrinology]] | [[Category:Endocrinology]] | ||
[[Category:Disease]] | |||
[[Category:Medicine]] | |||
[[Category:Parathyroid disorders]] | |||
[[Category:Up-To-Date]] | |||
Latest revision as of 22:18, 29 July 2020
|
Hypoparathyroidism Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Hypoparathyroidism future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Hypoparathyroidism future or investigational therapies |
|
FDA on Hypoparathyroidism future or investigational therapies |
|
CDC on Hypoparathyroidism future or investigational therapies |
|
Hypoparathyroidism future or investigational therapies in the news |
|
Blogs on Hypoparathyroidism future or investigational therapies |
|
Risk calculators and risk factors for Hypoparathyroidism future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Anmol Pitliya, M.B.B.S. M.D.[2]
Overview
In 1996, Winer and collegues demonstrated a reduction in calcium excretion in patients of hypoparathyroidism when treated with PTH 1-34 (teriparatide) when compared with treatment with calcitriol and calcium. PTH 1–34 (teriparatide) twice daily administered subcutaneoulsy provides a safe and effective alternative to calcitriol therapy and is capable of maintaining normocalcemia without hypercalciuria for at least 3 yr in patients with hypoparathyroidism. PTH 1-34 (teriparatide) has shown to improve the mental and physical health in hypoparathyroid patients.
Future or Investigational Therapies
Parathyroid hormone 1-34 (teriparatide)
- In 1996, Winer and collegues demonstrated a reduction in calcium excretion in patients of hypoparathyroidism when treated with PTH 1-34 (teriparatide) when compared with treatment with calcitriol and calcium.[1]
- Synthetic human was approved as a treatment for severe osteoporosis in 2002.
- PTH 1–34 (teriparatide) twice-daily shown to provide effective treatment of hypoparathyroidism and reduces the fluctuation in serum calcium levels at a lower total daily parathyroid hormone dose when compared to once daily regimen.[2]
- PTH 1–34 (teriparatide) twice daily administered subcutaneoulsy provides a safe and effective alternative to calcitriol therapy and is capable of maintaining normocalcemia without hypercalciuria for at least 3 yr in patients with hypoparathyroidism.[3]
- PTH 1–34 (teriparatide) is also safe and effective for treatment children with hypoparathyroidism when compared with conventional therapy.[4]
- PTH 1–34 (teriparatide) has shown to improve the mental and physical health in hypoparathyroid patients.[5]
References
- ↑ Winer KK, Yanovski JA, Cutler GB (1996). "Synthetic human parathyroid hormone 1-34 vs calcitriol and calcium in the treatment of hypoparathyroidism". JAMA. 276 (8): 631–6. PMID 8773636.
- ↑ Winer KK, Yanovski JA, Sarani B, Cutler GB (1998). "A randomized, cross-over trial of once-daily versus twice-daily parathyroid hormone 1-34 in treatment of hypoparathyroidism". J. Clin. Endocrinol. Metab. 83 (10): 3480–6. doi:10.1210/jcem.83.10.5185. PMID 9768650.
- ↑ Winer KK, Ko CW, Reynolds JC, Dowdy K, Keil M, Peterson D, Gerber LH, McGarvey C, Cutler GB (2003). "Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone-(1-34) versus calcitriol and calcium". J. Clin. Endocrinol. Metab. 88 (9): 4214–20. doi:10.1210/jc.2002-021736. PMID 12970289.
- ↑ Winer KK, Sinaii N, Reynolds J, Peterson D, Dowdy K, Cutler GB (2010). "Long-term treatment of 12 children with chronic hypoparathyroidism: a randomized trial comparing synthetic human parathyroid hormone 1-34 versus calcitriol and calcium". J. Clin. Endocrinol. Metab. 95 (6): 2680–8. doi:10.1210/jc.2009-2464. PMC 2902068. PMID 20392870.
- ↑ Santonati A, Palermo A, Maddaloni E, Bosco D, Spada A, Grimaldi F, Raggiunti B, Volpe R, Manfrini S, Vescini F (2015). "PTH(1-34) for Surgical Hypoparathyroidism: A Prospective, Open-Label Investigation of Efficacy and Quality of Life". J. Clin. Endocrinol. Metab. 100 (9): 3590–7. doi:10.1210/jc.2015-1855. PMID 26196949.